Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Blood blood.2023023616.

https://doi.org/10.1182/blood.2023023616

Published: 2024

Includes: Supplemental data

Journal Articles

Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4382–4383.

https://doi.org/10.1182/blood-2022-162859

Published: 2022

Journal Articles

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Blood (2022) 140 (Supplement 1): 384–387.

https://doi.org/10.1182/blood-2022-159707

Published: 2022

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Blood (2022) 140 (Supplement 1): 4447–4449.

https://doi.org/10.1182/blood-2022-162555

Published: 2022

Journal Articles

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Blood (2022) 140 (Supplement 1): 4415–4417.

https://doi.org/10.1182/blood-2022-157547

Published: 2022

Journal Articles

MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant

Amrita Y. Krishnan, Salomon Manier, Evangelos Terpos, Saad Usmani, Josephine Khan, Rachel Pearson, Suzette Girgis, Yue Guo, Dana McAleer, Yunsi Olyslager, Tobias Kampfenkel, Niels W.C.J. van de Donk

Blood (2022) 140 (Supplement 1): 10148–10149.

https://doi.org/10.1182/blood-2022-160173

Published: 2022

Journal Articles

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 896.

https://doi.org/10.1182/blood-2021-147915

Published: 2021

Journal Articles

Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 161.

https://doi.org/10.1182/blood-2021-148813

Published: 2021

Journal Articles

Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities

Lauren Willis, Emily S. Van Laar, Tristin Abair, Megan Whitney, Caitlin Costello, Amrita Y. Krishnan, Sagar Lonial, Sandra Kurtin, Joseph Mikhael, Ola Landgren

Blood (2021) 138 (Supplement 1): 4958.

https://doi.org/10.1182/blood-2021-145375

Published: 2021

Journal Articles

OM301, a Synthetic Polypeptide Containing the p53TA (Transactivation) Domain, Impairs Mitochondrial Activity and Survival of Myeloma Cells

Lokesh Nigam, Yinghui Zhu, Estelle Troadec, Enrico Caserta, Ada Dona', James F Sanchez, Amrita Y. Krishnan, Le Xuan Truong Nguyen, Guido Marcucci, Flavia Pichiorri

Blood (2021) 138 (Supplement 1): 2661.

https://doi.org/10.1182/blood-2021-151506

Published: 2021

Journal Articles

Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study

Blood (2021) 138 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2021-148723

Published: 2021

Journal Articles

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Amrita Y. Krishnan, Monique C. Minnema, Jesús G. Berdeja, Albert Oriol, Niels W.C.J. van de Donk, Paula Rodriguez-Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Raluca I. Verona, Xuewen Ma, Suzette Girgis, Shiyi Yang, Brandi W. Hilder, Jeffery Russell, Jenna D. Goldberg, Ajai Chari

Blood (2021) 138 (Supplement 1): 158.

https://doi.org/10.1182/blood-2021-146868

Published: 2021

Journal Articles

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Blood (2021) 138 (Supplement 1): 157.

https://doi.org/10.1182/blood-2021-147983

Published: 2021

Journal Articles

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Ada Dona', PhD, Domenico Viola, Enrico Caserta, PhD, Francesca Besi, PhD, James F Sanchez, PhD, Guido Marcucci, MD, Jonathan J Keats, PhD, Amrita Y. Krishnan, MD, Matt Coffey, PhD, Douglas W. Sborov, MDMSc, Gerard Nuovo, MD, Craig C Hofmeister, MDMPH, Flavia Pichiorri, PhD

Blood (2019) 134 (Supplement_1): 1816.

https://doi.org/10.1182/blood-2019-128740

Published: 2019

Journal Articles

Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up

Luciano J. Costa, MD PhD, Simona Iacobelli, Marcelo C. Pasquini, MD, Riddhi Modi, PhD, Luisa Giaccone, Joan Bladé, MD PhD, Stefan Schonland, Andrea Evangelista, Jose A. Perez-Simon, MD PhD, Parameswaran Hari, MBBS, MD, Elizabeth E. Brown, PhD MPH, Sergio A Giralt, MD, Francesca Patriarca, Edward A. Stadtmauer, MD FACP, Laura Rosinol, MD PhD, Amrita Y. Krishnan, MD, Goesta Gahrton, MD PhD, Benedetto Bruno, MD

Blood (2019) 134 (Supplement_1): 259.

https://doi.org/10.1182/blood-2019-121367

Published: 2019

Journal Articles

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

Amrita Y. Krishnan, MD, Krina K. Patel, MD MSc, Parameswaran Hari, MBBS, MD, Sundar Jagannath, MD, Ruben Niesvizky, MD, Rebecca W. Silbermann, MD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Eric Robert Fedyk, BSc, MSc, PhD, Antonio Palumbo, MD, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 140.

https://doi.org/10.1182/blood-2019-128007

Published: 2019

Journal Articles

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Blood (2019) 134 (Supplement_1): 4394.

https://doi.org/10.1182/blood-2019-126080

Published: 2019

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, MD, Amrita Y. Krishnan, MD, Nina D. Shah, MD, John M Burke, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Leslie L. Popplewell, MD FRCPA, Charalambos B. Andreadis, MD, Saurabh Chhabra, MD, Jeff P. Sharman, MD, Jonathan L. Kaufman, MD, Jonathon B. Cohen, MDMS, Ruben Niesvizky, MD, Thomas G. Martin, III, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS, FACP

Blood (2019) 134 (Supplement_1): 5329.

https://doi.org/10.1182/blood-2019-122754

Published: 2019

Journal Articles

Long-Term Follow up of Patients with HIV-Associated Non-Hodgkin Lymphoma (NHL) after Autologous Stem Cell Transplantation (ASCT)

Liana Nikolaenko, MD, Saro Armenian, DO, MPH, Joseph C. Alvarnas, MD, John A. Zaia, MD, Leanne Goldstein, DrPH, Maria Viviana Marroquin, Amrita Y. Krishnan, MD

Blood (2016) 128 (22): 4614.

https://doi.org/10.1182/blood.V128.22.4614.4614

Published: 2016

Journal Articles

Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?

Amrita Y. Krishnan, MD, Joycelynne Palmer, PhD, Auayporn P. Nademanee, MD, Robert Chen, Leslie L. Popplewell, MD, Nicole Tsai, MS, James F. Sanchez, PhD, Jennifer Simpson, Ricardo Spielberger, MD, Dave Yamauchi, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 3179.

https://doi.org/10.1182/blood.V126.23.3179.3179

Published: 2015

NARROW

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities

OM301, a Synthetic Polypeptide Containing the p53TA (Transactivation) Domain, Impairs Mitochondrial Activity and Survival of Myeloma Cells

Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Long-Term Follow up of Patients with HIV-Associated Non-Hodgkin Lymphoma (NHL) after Autologous Stem Cell Transplantation (ASCT)

Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only